PRECISION BIOSCIENCES INC

NASDAQ: DTIL (Precision BioSciences, Inc.)

Kemas kini terakhir: 17 May, 8:33PM

4.71

0.16 (3.52%)

Penutupan Terdahulu 4.55
Buka 4.64
Jumlah Dagangan 93,349
Purata Dagangan (3B) 156,130
Modal Pasaran 49,690,972
Harga / Jualan (P/S) 0.550
Harga / Buku (P/B) 1.03
Julat 52 Minggu
3.61 (-23%) — 13.44 (185%)
Tarikh Pendapatan 30 Jul 2025 - 4 Aug 2025
Margin Keuntungan 10.43%
Margin Operasi (TTM) -3,894.36%
EPS Cair (TTM) 1.04
Pertumbuhan Hasil Suku Tahunan (YOY) -95.60%
Jumlah Hutang/Ekuiti (D/E MRQ) 53.28%
Nisbah Semasa (MRQ) 6.34
Aliran Tunai Operasi (OCF TTM) -58.45 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -2.34 M
Pulangan Atas Aset (ROA TTM) -11.04%
Pulangan Atas Ekuiti (ROE TTM) 19.05%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok Precision BioSciences, Inc. Menaik Menaik

AISkor Stockmoo

0.9
Konsensus Penganalisis 3.5
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata 0.88

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
DTIL 50 M - - 1.03
ARWR 2 B - - 33.97
SPRY 1 B - - 5.32
GHRS 686 M - - 2.25
REPL 644 M - - 1.55
VIR 622 M - - 0.610

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 9.40%
% Dimiliki oleh Institusi 46.49%

Pemilikan

Nama Tarikh Syer Dipegang
Aquilo Capital Management, Llc 31 Mar 2025 726,149
887.05887.05655.90655.90424.75424.75193.60193.60-37.55-37.55Harga Sasaran MedianQ4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
3.61 (-23%) — 13.44 (185%)
Median 60.00 (1,173.89%)
Jumlah 1 Beli
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 21 May 2025 60.00 (1,173.89%) Beli 4.71
28 Mar 2025 60.00 (1,173.89%) Beli 4.70

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
20 May 2025 Pengumuman Sidoti Events, LLC's Virtual May Micro-Cap Conference
15 May 2025 Pengumuman Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
14 May 2025 Pengumuman Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
08 May 2025 Pengumuman Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
07 May 2025 Pengumuman Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
01 May 2025 Pengumuman Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
29 Apr 2025 Pengumuman Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
15 Apr 2025 Pengumuman Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
01 Apr 2025 Pengumuman Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
26 Mar 2025 Pengumuman Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
21 Mar 2025 Pengumuman iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting
21 Mar 2025 Pengumuman Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
20 Mar 2025 Pengumuman Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
19 Mar 2025 Pengumuman Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
17 Mar 2025 Pengumuman Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
Papar semua
5.505.505.125.124.744.744.364.363.983.98May 7May 7May 8May 8May 9May 9May 12May 12May 13May 13May 14May 14May 15May 15May 16May 16

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.1000.1000.0500.050-0.000-0.000-0.050-0.050-0.100-0.100MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda